Silence Therapeutics plc (SLNCF)
USD 0.95
(0.0%)
USD 0.95
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.05 Million GBP | 127.41% |
| 2022 | 6.62 Million GBP | 33.51% |
| 2021 | 4.95 Million GBP | 188.82% |
| 2020 | 1.71 Million GBP | 603.69% |
| 2019 | 244 Thousand GBP | 148.02% |
| 2018 | -508.16 Thousand GBP | 10.81% |
| 2017 | -569.74 Thousand GBP | -247.24% |
| 2016 | 386.94 Thousand GBP | 105.44% |
| 2015 | -7.11 Million GBP | 19.79% |
| 2014 | -8.86 Million GBP | -60.35% |
| 2013 | -5.53 Million GBP | -72.04% |
| 2012 | -3.21 Million GBP | -20.55% |
| 2011 | -2.66 Million GBP | -212.72% |
| 2010 | 2.36 Million GBP | 37.32% |
| 2009 | 1.72 Million GBP | -22.0% |
| 2008 | 2.2 Million GBP | -45.42% |
| 2007 | 4.04 Million GBP | 107.86% |
| 2006 | 1.94 Million GBP | 282.51% |
| 2005 | 509 Thousand GBP | 220.13% |
| 2004 | 159 Thousand GBP | -88.17% |
| 2003 | 1.34 Million GBP | 16.77% |
| 2002 | 1.15 Million GBP | 734.06% |
| 2001 | 138 Thousand GBP | -85.61% |
| 2000 | 959 Thousand GBP | -30.0% |
| 1999 | 1.37 Million GBP | 552.38% |
| 1998 | 210 Thousand GBP | 0.0% |
| 1997 | - GBP | 0.0% |
| 1996 | - GBP | 0.0% |
| 1995 | - GBP | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -2.04 Million GBP | -120.01% |
| 2024 Q1 | 10.19 Million GBP | 1253.65% |
| 2023 FY | 15.05 Million GBP | 127.41% |
| 2023 Q2 | 6.27 Million GBP | -8.29% |
| 2023 Q4 | 753 Thousand GBP | -36.78% |
| 2023 Q1 | 6.84 Million GBP | 654.97% |
| 2023 Q3 | 1.19 Million GBP | -81.01% |
| 2022 FY | 6.62 Million GBP | 33.51% |
| 2022 Q2 | 1.29 Million GBP | -62.55% |
| 2022 Q3 | 977 Thousand GBP | -24.32% |
| 2022 Q1 | 3.44 Million GBP | 151.24% |
| 2022 Q4 | 906 Thousand GBP | -7.27% |
| 2021 Q2 | 876 Thousand GBP | -45.49% |
| 2021 FY | 4.95 Million GBP | 188.82% |
| 2021 Q1 | 1.6 Million GBP | 75.82% |
| 2021 Q3 | 1.1 Million GBP | 26.03% |
| 2021 Q4 | 1.37 Million GBP | 24.28% |
| 2020 Q2 | 573 Thousand GBP | 0.0% |
| 2020 FY | 1.71 Million GBP | 603.69% |
| 2020 Q1 | 573 Thousand GBP | 123.83% |
| 2020 Q3 | -343 Thousand GBP | -159.86% |
| 2020 Q4 | 914 Thousand GBP | 366.47% |
| 2019 Q1 | -2.52 Million GBP | -11.54% |
| 2019 FY | 244 Thousand GBP | 148.02% |
| 2019 Q2 | -2.52 Million GBP | 0.0% |
| 2019 Q3 | -2.4 Million GBP | 4.83% |
| 2019 Q4 | -2.4 Million GBP | 0.0% |
| 2018 Q1 | -2.6 Million GBP | -26.32% |
| 2018 Q3 | -2.26 Million GBP | 13.07% |
| 2018 Q2 | -2.6 Million GBP | 0.0% |
| 2018 FY | -508.16 Thousand GBP | 10.81% |
| 2018 Q4 | -2.26 Million GBP | 0.0% |
| 2017 Q3 | -2.06 Million GBP | -8.55% |
| 2017 Q1 | -1.9 Million GBP | -16.2% |
| 2017 Q2 | -1.9 Million GBP | 0.0% |
| 2017 Q4 | -2.06 Million GBP | 0.0% |
| 2017 FY | -569.74 Thousand GBP | -247.24% |
| 2016 Q3 | -1.63 Million GBP | 29.96% |
| 2016 FY | 386.94 Thousand GBP | 105.44% |
| 2016 Q1 | -2.33 Million GBP | -20.45% |
| 2016 Q2 | -2.33 Million GBP | 0.0% |
| 2016 Q4 | -1.63 Million GBP | 0.0% |
| 2015 Q1 | -1.61 Million GBP | 34.67% |
| 2015 Q2 | -1.61 Million GBP | 0.0% |
| 2015 Q4 | -1.93 Million GBP | 0.0% |
| 2015 Q3 | -1.93 Million GBP | -19.77% |
| 2015 FY | -7.11 Million GBP | 19.79% |
| 2014 FY | -8.86 Million GBP | -60.35% |
| 2014 Q4 | -2.47 Million GBP | 0.0% |
| 2014 Q3 | -2.47 Million GBP | -26.6% |
| 2014 Q2 | -1.95 Million GBP | 0.0% |
| 2014 Q1 | -1.95 Million GBP | -13.06% |
| 2013 FY | -5.53 Million GBP | -72.04% |
| 2013 Q4 | -1.73 Million GBP | 0.0% |
| 2013 Q1 | -1.03 Million GBP | 0.0% |
| 2013 Q2 | -1.03 Million GBP | 0.0% |
| 2013 Q3 | -1.73 Million GBP | -67.33% |
| 2012 Q2 | - GBP | 0.0% |
| 2012 FY | -3.21 Million GBP | -20.55% |
| 2011 FY | -2.66 Million GBP | -212.72% |
| 2011 Q2 | - GBP | 0.0% |
| 2010 Q2 | - GBP | 0.0% |
| 2010 FY | 2.36 Million GBP | 37.32% |
| 2009 FY | 1.72 Million GBP | -22.0% |
| 2009 Q2 | - GBP | 0.0% |
| 2008 Q2 | - GBP | 0.0% |
| 2008 FY | 2.2 Million GBP | -45.42% |
| 2007 FY | 4.04 Million GBP | 107.86% |
| 2007 Q2 | - GBP | 0.0% |
| 2006 FY | 1.94 Million GBP | 282.51% |
| 2006 Q2 | - GBP | 0.0% |
| 2005 FY | 509 Thousand GBP | 220.13% |
| 2005 Q2 | - GBP | 0.0% |
| 2004 Q2 | - GBP | 0.0% |
| 2004 FY | 159 Thousand GBP | -88.17% |
| 2003 FY | 1.34 Million GBP | 16.77% |
| 2003 Q2 | - GBP | 0.0% |
| 2002 FY | 1.15 Million GBP | 734.06% |
| 2001 FY | 138 Thousand GBP | -85.61% |
| 2000 FY | 959 Thousand GBP | -30.0% |
| 1999 FY | 1.37 Million GBP | 552.38% |
| 1998 FY | 210 Thousand GBP | 0.0% |
| 1997 FY | - GBP | 0.0% |
| 1996 FY | - GBP | 0.0% |
| 1995 FY | - GBP | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 87.358% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 4812.573% |
| Qrons Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -8427.979% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -28.626% |
| BioStem Technologies, Inc. | 15.42 Million USD | 2.385% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 12218.212% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 31300.398% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.801% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 158.365% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -56.664% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -10616.726% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 617443.173% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -0.387% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -485296.518% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -53.737% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -22808.045% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 44190.776% |
| Mesoblast Limited | -35.16 Million USD | 142.814% |
| Marizyme, Inc. | 457.7 Thousand USD | -3189.695% |
| Genus plc | 178.7 Million USD | 91.574% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 93.159% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -24097.281% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3570.962% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 136981.818% |
| ContraFect Corporation | -154 Thousand USD | 9877.273% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 30214.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -19515.43% |
| IMV Inc. | -962.29 Thousand USD | 1664.692% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 3985.667% |
| MultiCell Technologies, Inc. | 49.32 USD | -30529097.08% |
| ONE Bio Corp. | 20.12 Million USD | 25.184% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 62.605% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -30691.411% |
| Q BioMed Inc. | -8988.00 USD | 167623.364% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 46.71% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 97720.591% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 66.056% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1418.971% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -21410.0% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 304158.966% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 15540.701% |
| GB Sciences, Inc. | -624.00 USD | 2413080.769% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 17602.441% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 7239042.308% |
| Enzolytics Inc. | 30.7 Thousand USD | -48932.825% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -3021.055% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 98.642% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 3026.474% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2338.839% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 96.324% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 170120.325% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 18057.28% |
| Kadimastem Ltd | -630.13 Thousand USD | 2489.477% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -1424.017% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 127324.335% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -8427.979% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -1009.463% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 52020.69% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -3245.68% |
| SYBLEU INC | 11.69 Thousand USD | -128636.32% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -226.758% |
| Bioxytran, Inc. | -8285.00 USD | 181838.081% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 4136.729% |
| Neutra Corp. | 14.33 Thousand USD | -104936.624% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 18462.195% |
| PureTech Health plc | -1.6 Million USD | 1039.301% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1603.841% |
| IXICO plc | 3.27 Million USD | -360.459% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 2269.597% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 940.704% |
| CSL Limited | 7.7 Billion USD | 99.805% |
| Cellectis S.A. | 18 Thousand USD | -83550.0% |